Sphingomonas Paucimobilis Bacteria Isolation From Different Clinical Samples Of a Nosocomial Infection In Erbil City

Abstract

Abstract
 Background: Sphingomonas paucimobilis is a gram-negative pathogen that causes urinary tract infections, diarrhea, septicemia, and wound infections. Due to the spread of patients with high mortality but low mortality in Sphingomonas paucimobilis, it has been isolated from different clinical samples and is increasing antibiotic resistance all over the world.
 
 Objectives: The aim of our research was to look at the epidemiology, antibiotic susceptibility series, and pathogenic potential of clinical samples from Erbil's Rizgary and Raparin hospitals.
 
 Materials and Methods: A total of 2582 samples were reviewed from different clinical samples from Rizgary Hospital and Raparin Hospital from male and female, we found 24 Sphingomonas paucimobilis isolates, identified by using microscopical, morphological, biochemical tests and Vitek2 compact system according to the standard protocol against Ampicillin/Sulbactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Imipenem, Tobramycin, Ciprofloxacin, Lev- ofloxacin, Trimethoprim. using Vitek 2 compact system.
 Results: 24 total positive results of Sphingomonas paucimobilis isolated from 2582 different clinical specimens the highest percentage of Sphingomonas paucimobilis was isolated from female samples (65%) while from male (35%) wen performing antibiotic susceptibility the highest resistance rate was Trimethoprim (66.66%), followed by To bramycin (50%), Ciprofloxacin (50%) and Levofloxacin (41.66%), respectively in contrast the highest effective antibiotic against Sphingomonas paucimobilis was Cefepime (75%), Imipenem (75%), followed by Ceftriaxone (66.66%), Ceftazidime (66.66%), Cefazolin (66.66%), Ampicillin/Sulbactam (66.66%) Conclusion: Morbidity attribute to antibiotic resistance to third generation cephalosporin resistant, Sphingomonas paucimobilis resistant is significant, if prevailing resistance trends continue, high societal and economic costs can be expected. Better management of antibiotic use, and infection control is needed to avoid infections that caused by drug resistant pathogens like Sphingomonas paucimobilis.